Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Vantage Specialty Ingredients
EIR
•Vantage Specialty Ingredients•February 8, 2016

Vantage Specialty Ingredients – FDA EIR, Feb 8, 2016

Record Details

Vantage Specialty Ingredients, a firm involved in relabeling bulk Active Pharmaceutical Ingredients (APIs) and repackaging various chemicals and pharmaceutical necessities, underwent a U.S. FDA cGMP surveillance inspection from February 8 to 10, 2016. The inspection, guided by Compliance Programs 7356.002F (API Process Inspection) and 7356.002B (Drug Repackers and Relabelers), as well as Q7 Good Manufacturing Practice Guidance for APIs, covered the company's materials, packaging and labeling, facilities and equipment, quality, and laboratory control systems. A significant finding was the firm's reported operational shift, confirming they no longer repackage API materials and have downsized related activities. Crucially, the inspection concluded without the issuance of an FDA Form 483, indicating no formal objectionable conditions were identified. However, investigators verbally communicated one specific deficiency: the company was not conducting annual GMP training for its personnel. In contrast, a previous inspection in August 2013 had resulted in two formal observations regarding deficiencies in the quality unit and the lack of appropriate validation for test results listed on API reports of analyses. For the current inspection, despite the verbal observation, the overall outcome was classified as "No Action Indicated" (NAI), suggesting general compliance. Nevertheless, the company was expected to address the identified lapse in annual GMP training to ensure ongoing adherence to regulatory expectations.

Company
Vantage Specialty Ingredients
Inspection date
February 8, 2016
Product type
Drugs
Office
New Jersey District Office
People
  • Melissa T. Roy (Regulatory Counsel at FDA with a PharmD and JD)
  • Robert Falcone (company_representative)
  • Stephen J. Mottola (issuing_officer)
  • Guerlain Ulysse (Investigator)
View Company Profile

ID · d38fc29f-8a57-4938-a22e-e0ae6ee49196

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Vantage Specialty Ingredients
  • 483 - 2022-05-02May 2, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Vantage Specialty Ingredients
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.